Advances in Dermatology and Allergology · 2019 · 19 citations · 13 references
MedicineDermatologyOncologyCancer ImmunologyImmunotherapyMetastasisCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmunotherapy For Skin CancerMelanoma PharmacotherapyCheckpoint Antagonist TherapyImmune Checkpoint Inhibitor TherapyImmune Checkpoint ReceptorsImmune Checkpoint ResistanceMelanoma ImmunotherapyMetastatic Melanoma To SkinMetastatic Melanoma TreatmentResistance To Checkpoint Inhibitors
The use of immunotherapy in older patients remains challenging due to very few data on the efficacy and safety of treatment in this group. Aim: To analyse the efficacy and safety of immunotherapy with checkpoint inhibitors in older patients ( 70 years) with metastatic melanoma. Material and methods: In the Maria Skodowska-Curie Institute -Oncology Centre, between 2011 and 2017, 318 non-resectable or metastatic melanoma patients were treated with immune checkpoint inhibitors: anti-CTLA-4 or/ and anti-PD-1. Eighty-two patients were 70 years (median age: 76 years; range: 70-90 years). Among this group 10% of patients had brain metastases, 24% of patients had BRAF mutant melanoma, and co-morbidities were present in 86% of patients (mainly hypertension, cardiovascular diseases and/or diabetes). Results: Median PFS and OS were similar in patients < 70 years and 70 years. In the group of patients 70 years old, the 2-year OS rate (from the start of immunotherapy) was 27%, and in patients aged < 70 it was 28% (p = NS). Two-year progression-free survival was 13.7% in the group of patients 70 years old and in patients aged < 70 it was 13% (p = NS). Patients 70 years of age were significantly less likely to have a BRAF mutation (p = 0.020). The presence of co-morbidities was not associated with an increased risk of immunotherapy (p = 0.790). Conclusions: The survival and toxicity profile in the older patients treated with immune checkpoint inhibitors are similar to younger patients. Therefore, the age as a clinical factor should not exclude this population from the most effective therapy used nowadays in melanoma treatment.
13
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14